Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Biphenotypic, Acute 2Patient Preference 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Whole-Body Irradiation 4Cyclophosphamide 4fludarabine 3Tacrolimus 3Mycophenolic Acid 3Vorinostat 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Busulfan 2Azacitidine 2venetoclax 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1Triamcinolone 1Thiotepa 1Specimen Handling 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Lenalidomide 1Etoposide 1Cyclosporine 1Cord Blood Stem Cell Transplantation 1Biopsy 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Anemia, Refractory, with Excess of Blasts × decitabine and cedazuridine drug combination × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡